Literature DB >> 12869982

Fibrin sealants in clinical practice.

David M Albala1.   

Abstract

Fibrin sealants are used in a wide range of surgeries, primarily as hemostatic agents, but also to assist tissue sealing and wound healing. While all fibrin sealants contain fibrinogen and thrombin, they differ in their final composition. This affects the properties of the resulting fibrin clot and may influence their use in different surgical procedures. Sealants with high concentrations of fibrinogen tend to produce stronger clots, whereas those containing higher concentrations of thrombin form clots rapidly. This is essential when rapid hemostasis is required to stop blood loss (e.g. suturing of blood vessels). However, in situations that require careful adjustment of tissue (e.g. a skin flap) a slower clot formation is advantageous. Some sealants are supplemented with factor XIII and this may increase the tensile strength and stability of the clot and improve hemostasis. Antifibrinolytic agents (e.g. aprotinin and aminocaproic acid) increase the lifespan of the clot by inhibiting fibrinolysis. Fibrin sealants containing aprotinin may have an added advantage when used on surgical sites with naturally high concentrations of fibrinolytic agents. The physical properties of the fibrin sealants also vary. For example, the fibrinogen component is relatively viscous and requires a lot of force to inject it through a long catheter. Fibrin sealants with a fibrinogen component of low viscosity are easier to use than highly viscous solutions in surgical situations where the sealant is applied by a catheter. Until recently, the use of fibrin sealants in the USA has been limited to noncommercial products--'home-brews'. The fibrinogen concentration of these products can vary between preparations, with subsequent variation in the mechanical strength of the clot making handling difficult. The introduction of commercial sealants into the USA with consistent composition should reduce the varying performance of fibrin sealants, although autologous and point-of-use prepared sealants may still vary. Consistency of performance is expected to result in an increased use of fibrin sealants both in established and novel fields of surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869982     DOI: 10.1016/S0967-2109(03)00065-6

Source DB:  PubMed          Journal:  Cardiovasc Surg        ISSN: 0967-2109


  22 in total

1.  Hemostasis during urologic surgery: fibrin sealant compared with absorbable hemostat.

Authors:  David M Albala; Jerome B Riebman; Richard Kocharian; Bogdan Ilie; John Albanese; Jessica Shen; Liza Ovington; Jonathan Batiller
Journal:  Rev Urol       Date:  2015

2.  Plasmatic [corrected] factor XIII reduces severe pleural effusion in children after open-heart surgery.

Authors:  M Schroth; U Meißner; R Cesnjevar; M Weyand; H Singer; W Rascher; J Klinge
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

3.  Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials.

Authors:  Priscilla S Briquez; Kristen M Lorentz; Hans M Larsson; Peter Frey; Jeffrey A Hubbell
Journal:  Biomaterials       Date:  2017-04-29       Impact factor: 12.479

4.  Multiscale mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water.

Authors:  André E X Brown; Rustem I Litvinov; Dennis E Discher; Prashant K Purohit; John W Weisel
Journal:  Science       Date:  2009-08-07       Impact factor: 47.728

5.  Osteogenic properties of calcium phosphate ceramics and fibrin glue based composites.

Authors:  Damien Le Nihouannen; Afchine Saffarzadeh; Eric Aguado; Eric Goyenvalle; Olivier Gauthier; Françoise Moreau; Paul Pilet; Reiner Spaethe; Guy Daculsi; Pierre Layrolle
Journal:  J Mater Sci Mater Med       Date:  2007-02       Impact factor: 3.896

6.  Platelet activation by collagen provides sustained release of anabolic cytokines.

Authors:  Sophia Harrison; Patrick Vavken; Sherwin Kevy; May Jacobson; David Zurakowski; Martha M Murray
Journal:  Am J Sports Med       Date:  2011-03-11       Impact factor: 6.202

Review 7.  Design strategies and applications of tissue bioadhesives.

Authors:  Mohammadreza Mehdizadeh; Jian Yang
Journal:  Macromol Biosci       Date:  2012-12-06       Impact factor: 4.979

8.  Fibrin concentration affects ACL fibroblast proliferation and collagen synthesis.

Authors:  Patrick Vavken; Shilpa M Joshi; Martha M Murray
Journal:  Knee       Date:  2010-01-18       Impact factor: 2.199

9.  Bone tissue formation in sheep muscles induced by a biphasic calcium phosphate ceramic and fibrin glue composite.

Authors:  Damien Le Nihouannen; Afchine Saffarzadeh; Olivier Gauthier; Françoise Moreau; Paul Pilet; Reiner Spaethe; Pierre Layrolle; Guy Daculsi
Journal:  J Mater Sci Mater Med       Date:  2007-07-10       Impact factor: 3.896

10.  The effects of soluble growth factors on embryonic stem cell differentiation inside of fibrin scaffolds.

Authors:  Stephanie M Willerth; Tracy E Faxel; David I Gottlieb; Shelly E Sakiyama-Elbert
Journal:  Stem Cells       Date:  2007-06-21       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.